Authors : Xin Cui, Yueming Zhu, Lidan Zeng, Mengyuan Zhang, Amad Uddin, Theresa W Gillespie, Lauren E McCullough, Shaying Zhao, Mylin A Torres, Yong Wan Source : This study elucidates a molecular mechanism by which Retatrutide overcomes therapeutic resistance in obese triple-negative breast cancer (TNBC)
Initially developed for type 2 diabetes, they are now recognized for their broad impact on weight regulation, inflammation, cardiovascular health, and neuroprotectiondomains central to longevity and healthy aging
These FDA-approved medications are prescribed following a thorough virtual consultation
Natural human GLP-1 exists primarily as GLP-1(7-36) amide, a peptide that is rapidly degraded by DPP-4, resulting in a half-life of only 2 to 3 minutes
Based on Phase 2 clinical trial data published in the New England Journal of Medicine (2023), retatrutide shares a side-effect profile broadly consistent with other GLP-1 receptor agonist class medicines, though the addition of glucagon receptor agonism may introduce some distinct effects
This process typically involves a clinical assessment, discussion of goals, and ongoing monitoring to guide dosing safely.
